Multaq Lawsuit Filed Over Failure to Warn About Liver Injury Risks

|

Sanofi-Aventis faces a product liability lawsuit filed by multiple plaintiffs, which alleges that the drug maker withheld information about the risk of serious liver injury associated with side effects of Multaq. 

The complaint (PDF) was filed in the U.S. District Court for the Middle District of North Carolina on January 25, by Ruth Amanda Hardin and Michael Clay, both of North Carolina, Eric Biggs of Pennsylvania, Virginia Roberts of Oklahoma, and by Mary Jo Meyer of Indiana, who brought a claim on behalf of herself and the estate of James Meyer.

Hardin, Biggs, and James Meyer suffered serious drug-induced liver injuries due to the use of Multaq. Clay suffered liver damage, heart failure and other cardiovascular problems.

Sports-Betting-Addiction-Lawsuits
Sports-Betting-Addiction-Lawsuits

Multaq (dronedarone) is a prescription treatment for abnormal heart rhythms, which was introduced by Sanofi-Aventis in July 2009.

In January 2011, the FDA required new warnings about the potential risk of liver failure or liver injury from Multaq, indicating that at least two patients on Multaq suffered acute liver failure that required them to get a liver transplant.

In December 2011, the FDA issued another Multaq safety warning, advising that the drug should not be used in patients whose abnormal heart rhythms were permanent. It also required the manufacturer, Merck & Co., to add additional safety warnings and contraindications to the label.

“Plaintiffs allege that Defendants had an established duty to warn of the dangers of using Multaq. Defendants knew or should have known of the dangers generally known to the scientific community at the time they manufactured and distributed Multaq,” the lawsuit filed this week indicates. “Defendants failed to provide warning of the dangers of using Multaq, specifically failing to warn Plaintiffs and their physicians regarding known dangers including the danger of life-threatening liver and cardiovascular injuries.”

The complaint presents claims against the drug maker for failure to warn, designing a defective drug, negligence, and breach of warranty, seeking both compensatory and punitive damages.


0 Comments


Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

MORE TOP STORIES

As lawyers continue to review records on more than 500 Suboxone tooth decay lawsuits, the MDL judge has outlined the process for identifying a smaller group that will move into the next discovery phase.
A federal judge wants lawyers involved in hair relaxer lawsuits to provide an update this week on the status of discovery proceedings for a pool of cases being considered for bellwether trial dates.
Two Covidien Parietex Optimized Composite hernia mesh lawsuits have been chosen to be prepared to potentially serve as the third Covidien hernia mesh bellwether trial.